drugset / Trial / NCT02270801

Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy

NCT02270801

Phase 3 Unknown 30 enrolled Shandong University
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial is undertaking by Qilu Hospital of Shandong University, aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.

Timeline

Start
2014-10
Primary completion
2017-01
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Intravenous